Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, has appointed Thomas Rohrer as Vice President of Bioconjugation.

His appointment follows a recently announced investment to establish cGMP bioconjugation capabilities at its Devens, Massachusetts site.

Thomas brings over four decades of experience in biological process development and clinical manufacturing—including 30 years in licensed biological production.

Throughout his career, he has successfully delivered complex biological programmes for both clinical and commercial applications, including mammalian, microbial, vaccine, and gene therapy drug substances.

During his 16-year tenure at Lonza, Thomas led teams across multiple sites and departments, including Biopharmaceutical Manufacturing, Antibody Drug Conjugation, Biochemical Technologies, Project Evaluation, and Commercial Development. His career also includes senior roles at Human Genome Sciences (now part of GSK), Otsuka America Pharmaceutical, Guidepoint Global, Gentz Biopharmaceutical Consulting, and most recently, Senior Director of Bioconjugate Technology Support at Samsung Biologics.

Thomas holds a Bachelor of Science in Biochemistry from Shepherd University and pursued further studies at the University of Maryland’s Graduate School of Engineering in the Department of Chemical and Biochemical Engineering, and the National Institute for Public Health and the Environment in the Netherlands (Rijkes Institute voor de Volksgezondheid).

He has authored multiple publications and presentations on the manufacturing of antibody drug conjugates and bioprocesses used for the manufacturing of biological therapeutics.

Welcoming him to the team, Rohtash Kumar, Senior Vice President of Development Operations and Chief Technology Officer at Veranova, said, “His invaluable experience and thought leadership in biological manufacturing will be critical as we continue to build and grow our bioconjugation offering in Devens, providing a more comprehensive suite of services to partners developing Antibody Drug Conjugates and other bioconjugates.”

Headquartered in Devens, Massachusetts, Veranova specialises in the process development and manufacturing of complex APIs, including small molecules, antibody-drug conjugates, oligonucleotides, and peptides. The company has operations in North America and Europe.